Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors

Molecular Pharmacology

Volumn 66, Issue 3, 2004, Pages 675-682

  Damaj, M Imad ^a,d,e   Carroll, F Ivy ^b   Eaton, J Brek ^c   Navarro, Hernan A ^b   Blough, Bruce E ^b   Mirza, Sadiq ^a   Lukas, Ronald J ^c   Martin, Billy R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b RTI INTERNATIONAL   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DOPAMINE; DRUG METABOLITE; HYDROXYAMFEBUTAMONE; NICOTINE; NICOTINIC RECEPTOR; NORADRENALIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; ENANTIOSELECTIVITY; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; HYPOTHERMIA; ISOMER; LOCOMOTION; MALE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NORADRENALIN UPTAKE; PRIORITY JOURNAL; RACEMIZATION; RAT; SMOKING CESSATION;

ANIMALS; BEHAVIOR, ANIMAL; BUPROPION; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PAIN; RECEPTORS, NICOTINIC; SWIMMING; SYMPORTERS;

EID: 4944267468     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.001313     Document Type: Article

References (29)

1. Aceto MD, Martin BR, Uwaydah IM, May EL, Harris LS, Izazola-Conde C, Dewey WL, Bradshaw TJ, and Vincek WC (1979) Optically pure (+)-nicotine from (±)-nicotine and biological comparisons with (-)-nicotine. J Med Chem 22:174-177.
2. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, et al. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56:395-401.
3. Bencherif M and Lukas R (1993) Cytochalasin modulation of nicotinic cholinergic receptor expression and muscarinic receptor function in human TE671/rd cells: a possible functional role of the cytoskeleton. J Neurochem 61:852-864.
4. Bondarev ML, Bondareva TS, Young E, and Glennon RA (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85-93.
5. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, and Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Welbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11:133-141.
6. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
7. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein OK, and Lukas RJ (2003) Characterization of human alpha4beta2 nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1q human epithelial cells. Mol Pharmacol 64:1283-1294.
8. Eshleman AJ, Wolfrum K, Mash DC, Christensen K, and Janowsky A (2001) Drug interactions with the dopamine transporter in cryopreserved human caudate. J Pharmacol Exp Ther 296:442-449.
9. Fang QK, Han ZY, Grover P, Kessler D, Senanayake CH, and Wald SA (2000) Rapid access to enantiopure bupropion and its major metabolite by stereospeciflc nucleophilic substitution on a-ketotriflate. Tetrahedron 11:3659-3663.
10. Findlay JW, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, and Blum MR (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 21:127-135.
11. Fryer JD and Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine. J Pharmacol Exp Ther 288:88-92.
12. Gentry CL, Wilkins LH Jr, and Lukas EJ (2003) Effects of prolonged nicotinic ligand exposure on function of heterologously expressed, human α4β2- and α4β4-nicotinic acetylcholine receptors. J Pharmacol Exp Ther 304:206-216.
13. Golden RN, De Vane CL, Laizure SC, Rudorfer MV, Sherer MA, and Potter WZ (1988) Bupropion in depression. II. The role of metabolites in clinical outcome. Arch Gen Psychiatry 45:145-149.
14. Henningfield JE, Cohen C, and Slade JD (1991) Is nicotine more addictive than cocaine? Br J Addiction 86:565-569.
15. Hysu P-H, Singh A, Giargiari TD, Dunn JA, Ascher JA, and Johnston JA (1997) Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 37:737-743.
16. Kuhar MJ, McGirr KM, Hunter RG, Lambert PD, Garrett BE, and Carroll FI (1999) Studies of selected phenyltropanes at monoamine transporters. Drug Alcohol Depend 56:9-15.
17. Lukas RJ (1986) Characterization of curaremimetic neurotoxin binding sites on membrane fractions derived from the human medulloblastoma clonal line, TE671. J Neurochem 36:1936-1941.
18. Lukas RJ (1989) Nicotinic acetylcholine receptor diversity: agonist binding and functional potency. Progr Brain Res 79:117-127.
19. Lukas RJ (1993) Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J Pharmacol Exp Ther 265:294-302.
20. Lukas RJ, Fryer JD, Eaton JB, and Gentry CL (2002) Some methods for studies of nicotinic acetylcholine receptor pharmacology, in Nicotinic Receptors and the Nervous System (Levine ED ed) pp 3-27, CRC Press, Boca Raton.
21. Lukas RJ, Norman SA, and Lucero L (1993) Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y neuroblastomal human clonal line. Mol Cell Neurosci 4:1-12.
22. Martin P, Massol J, Colin JN, Lacomblez L, and Puech AJ (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23:187-194.
23. 3H]norepinephrine. J Pharmacol Exp Ther 302:1113-1122.
24. Paczkowski FA, Bryan-Lluka LJ, Porzge P, Bruss M, and Bonisch H (1999) Comparison of the pharmacological properties of cloned rat, human and bovine norepinephrine transporters. J Pharmacol Exp Ther 290:761-767.
25. Porsolt RD, Bertin A, and Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
26. Slemmer JE, Martin BR, and Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321-327.
27. Stathis M, Scheffel U, Lever SZ, Boja JW, Carroll FI, and Kuhar MJ (1995) Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berl) 119:376-384.
28. Tallarida RJ and Murray RB (1987) Manual of Pharmacological Calculations with Computer Programs. Springer-Verlag, New York.
29. Welch RM, Lai AL, and Schroeder DH (1987) Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17:287-298.